AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Ardelyx, Inc.
Video analysis: ARDX
All videosNo video analysis for this stock yet. Request one from our team.
News: ARDX
Ardelyx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced its participation in the following investor conferences:
Freestone Grove Partners LP Buys Shares of 253,692 Ardelyx, Inc. $ARDX
Freestone Grove Partners LP bought a new position in Ardelyx, Inc. (NASDAQ: ARDX) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 253,692 shares of the biopharmaceutical company's stock, valued at approximately $1,294,000. Freestone Grove Partners LP owned 0.10% of
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Ardelyx (ARDX)
Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations Ardelyx shares fell nearly 18% on August 7, 2026 after the Company cut its full-year IBSRELA revenue guidance -- a range it had reiterated just over three months earlier. Levi & Korsinsky is investigating potential securities law violations
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)
Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's s
ARDX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Ardelyx (ARDX)
NEW YORK--(BUSINESS WIRE)--Every 100 shares of Ardelyx (NASDAQ: ARDX) held into August 7, 2026 lost about $87 in value as the stock fell 17.86% to close at $4.00 following the Company's second quarter report. If you held ARDX shares and lost money, you are encouraged to submit your loss information for review. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The damage came alongside numbers the Company itself called records. Arde.
ARDX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Ardelyx
Ardelyx cut its 2026 IBSRELA revenue guidance by up to $80 million on August 6, 2026, citing payer utilization-management restrictions -- and shares fell nearly 18% the next session. NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Payer coverage restrictions allegedly cost Ardelyx (NASDAQ: ARDX) shareholders roughly 18% of their investment on August 7, 2026, when the stock closed at $4.00 after the Company attributed a full-year IBSRELA guidance cut to increased step edits and more stringent prior authorizations.
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
Ardelyx Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX) PR Newswire
Ardelyx Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Ardelyx (ARDX)
ARDX closed at $4.00 on August 7, 2026 -- down 17.86% -- after Q2 product revenue of $118.1 million came in below consensus and analysts cut price targets in accord. NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Ardelyx (NASDAQ: ARDX) shares closed at $4.00 on August 7, 2026, an 17.86% single-session decline, after the Company reported second quarter 2026 product revenue of $118.1 million and a loss of approximately $(0.07) per share -- both below consensus estimates.
